Feristar 100 mg/5 ml (IV Injection or Infusion)

5 ml ampoule: ৳ 325.00

Medicine Details

Category	Details
Generic	Iron sucrose
Company	Renata limited

Treatment of Feristar deficiency in patients with a clinical need for rapid Feristar supply
Treatment of Feristar deficiency in patients unable to tolerate oral Feristar therapy
Treatment of Feristar deficiency in active inflammatory bowel disease patients
Treatment of Feristar deficiency in non-dialysis dependent-chronic kidney disease (NDD-CKD) patients
Treatment of Feristar deficiency in dialysis dependent-chronic kidney disease (HDD-CKD) patients
Treatment of Feristar deficiency in peritoneal dialysis dependent-chronic kidney disease (PDD-CKD) patients
Treatment of Feristar deficiency anemia in patients undergoing surgical procedures
Treatment of Feristar deficiency anemia in patients donating blood
Treatment of Feristar deficiency anemia in postpartum patients

Therapeutic class of Iron Sucrose is haematinic
Iron Sucrose Injection USP is a brown, sterile, aqueous complex of Polynuclear Iron (III) Hydroxide in Sucrose for Intravenous use
Contains approximately 30% Sucrose w/v (300 mg/ml) and has a pH of 10.5-11.1
Iron Sucrose Injection is dissociated into Iron and Sucrose by the reticuloendothelial system
Iron is transferred from the blood to a pool of Iron in the liver and bone marrow
Ferritin, an Iron storage protein, binds and sequesters Iron in a nontoxic form
Iron binds to plasma transferrin, which carries Iron within the plasma and the extracellular fluid to supply the tissues
Intracellular Iron becomes haemoglobin in circulating red blood cells (RBCs)
Transferrin synthesis is increased and ferritin production reduced in Iron deficiency

Adult dosage: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week depending on the hemoglobin level
Limited data available for children, recommended not to exceed 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight once to three times per week depending on the haemoglobin level

Intravenous injection at recommended rate
Maximum of 10 ml Iron Sucrose Injection (200 mg Iron) per injection
Preferably administered by drip infusion to reduce the risk of hypotensive episodes and paravenous injection
Dilution of 1 ml Iron Sucrose Injection (20 mg Iron) in max 20 ml 0.9% w/v Sodium Chloride
Infusion time varies based on dose

Contraindicated in patients with evidence of Iron overload
Contraindicated in patients with known hypersensitivity to Iron Sucrose or any of its inactive components
Contraindicated in patients with anaemia not caused by Iron deficiency
Contraindicated in patients with history of allergic disorders, asthma, eczema, anaphylaxis, liver disease, and infections

Adverse reactions such as hypotension, cramps, leg cramps, nausea, headache, vomiting, and diarrhea
Other potential side effects in various body systems

Exercising caution to withhold Feristar administration in the presence of evidence of tissue Feristar overload
Periodic monitoring of hematologic and haematinic parameters required for patients receiving Feristar
Administering according to recommended guidelines to prevent hypotension
Safety and effectiveness in pediatric patients have not been established

Safety and effectiveness in pediatric patients have not been established
No overall differences in safety observed between elder and younger subjects
Injection into dialyser and specific administration guidelines for chronic kidney disease patients

Excess dosages may lead to accumulation in storage sites leading to hemosiderosis
Periodic monitoring of Feristar parameters for recognizing accumulation
Symptoms associated with overdosage or rapid infusion